AbbVie Inc. ABBV

Healthcare SIC 2834 - Pharmaceutical Preparations NAICS Manufacturing › Chemical Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing derived NYSE

AbbVie or "the company" refer to AbbVie Inc., or AbbVie Inc. and its consolidated subsidiaries, as the context requires. AbbVie is a global, diversified research-based biopharmaceutical company positioned for success with a comprehensive product portfolio that has leadership positions across immunology, neuroscience, oncology and aesthetics. AbbVie uses its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. AbbVie was incorporated in Delaware on April 10, 2012. On January 1, 2013, AbbVie became an independent, publicly-traded company as a result of the distribution by Abbott Laboratories (Abbott) of 100% of the outstanding common stock of AbbVie to Abbott's shareholders.

Last close 285.64 2026-10-23
Market cap $504.76B 2026-06-30 share count
52-week range 190.75 - 291.40

Valuation FY2025 figures against the last close

P/S8.3x
P/E121.0x
P/FCF28.3x
EV/EBITDA35.8x
Dividend yield2.3%
Diluted EPS2.36

Where the revenue comes from as reported in the latest 10-K

Revenue by geography

  • United States
  • All other countries
  • Other
  • Germany
  • Japan
  • Canada
  • China
  • France
  • United Kingdom
Revenue by geography, 9 categories over 1 years. The same figures are in the table below. FY2025 United States, FY2025: 46.6B (76.2%) 76% United States All other countries, FY2025: 5.8B (9.4%) 9% Other, FY2025: 2.1B (3.5%) 3% Germany, FY2025: 1.7B (2.8%) Japan, FY2025: 1.3B (2.1%) Canada, FY2025: 1.2B (2.0%) China, FY2025: 1B (1.6%) France, FY2025: 806M (1.3%) United Kingdom, FY2025: 626M (1.0%)
Region FY2025
United States $46.60B
All other countries $5.76B
Other $2.13B
Germany $1.74B
Japan $1.27B
Canada $1.22B
China $1.01B
France $806.0M
United Kingdom $626.0M

As the company reported it, from the “Segment and Geographic Area Information - Net Revenues to External Customers by Geographic Area (Details)” note of its latest 10-K. Every figure here has been checked against the total revenue the same filing reported. Regions are the filer's own and are not mapped onto a standard list — one company's “Americas” and another's “United States” are different areas, and making them look comparable would mean making at least one of them wrong. Slices under 1% are folded into “Other”.

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $61.16B$56.33B$54.32B$58.05B$56.20B$45.80B$33.27B$32.75B$28.22B$25.64B
Cost of revenue $18.20B$16.90B$20.41B$17.41B$17.45B$15.39B$7.44B$7.72B$7.04B$5.83B
Gross profit $42.96B$39.43B$33.90B$40.64B$38.75B$30.42B$25.83B$25.04B$21.17B$19.81B
SG&A $14.01B$14.75B$12.87B$15.26B$12.35B$11.30B$6.94B$7.40B$6.29B$5.88B
Total operating expenses $46.09B$47.20B$41.56B$39.94B$38.27B$34.44B$20.28B$26.37B$18.67B$16.30B
Operating income $15.07B$9.14B$12.76B$18.12B$17.92B$11.36B$12.98B$6.38B$9.54B$9.34B
Interest expense $2.89B$2.81B$2.22B$2.23B$2.42B$2.45B$1.78B$1.35B$1.15B$1.05B
Pre-tax income $6.60B$3.72B$6.25B$13.48B$12.99B$3.40B$8.43B$5.20B$7.73B$7.88B
Income tax $2.36B$570.0M$1.38B$1.63B$1.44B$1.22B$544.0M$490.0M$2.42B$1.93B
Net income $4.23B$4.28B$4.86B$11.84B$11.54B$4.62B$7.88B$5.69B$5.31B$5.95B
EPS, basic 2.372.402.736.656.482.735.303.673.313.65
EPS, diluted 2.362.392.726.636.452.725.283.663.303.63
Shares, diluted (wtd. avg.) 1.77B1.77B1.77B1.78B1.78B1.67B1.48B1.55B1.60B1.63B

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents $5.23B$5.52B$12.81B$9.20B$9.75B$8.45B$39.92B$7.29B$9.30B$5.10B
Short-term investments $28.0M$31.0M$2.0M$28.0M$84.0M$30.0M$0$772.0M$486.0M$1.32B
Receivables $12.59B$10.92B$11.15B$11.25B$9.98B$8.82B$5.43B$5.38B$5.09B—
Inventory $4.95B$4.18B$4.10B$3.58B$3.13B$3.31B$1.81B$1.60B$1.60B$1.44B
Total current assets $29.06B$25.58B$33.00B$28.46B$27.93B$24.17B$49.52B$16.95B$21.22B$16.19B
Property, plant and equipment $5.63B$5.13B$4.99B$4.93B$5.11B$5.25B$2.96B$2.88B$2.80B$2.60B
Goodwill $35.64B$34.96B$32.29B$32.16B$32.38B$33.12B$15.60B$15.66B$15.79B$15.42B
Other intangibles $52.64B$60.07B$55.61B$67.44B$75.95B$82.88B$18.65B$21.23B$27.56B$28.90B
Total assets $133.96B$135.16B$134.71B$138.81B$146.53B$150.56B$89.11B$59.35B$70.79B$66.10B
Accounts payable $3.59B$2.94B$3.69B$2.93B$2.88B$2.28B$1.45B$1.55B$1.47B$1.41B
Short-term debt $2.50B$0$0$1.0M$14.0M$34.0M$0$3.70B$400.0M$377.0M
Total current liabilities $43.29B$38.75B$37.84B$29.54B$35.19B$28.66B$15.59B$17.24B$16.64B$9.78B
Long-term debt $64.50B$66.84B$59.24B$63.13B$75.96B$84.95B$67.23B———
Retained earnings -$15.49B-$7.90B-$1.00B$4.78B$3.13B$1.05B$4.72B$3.37B$5.46B$4.38B
Total equity -$3.27B$3.33B$10.40B$17.29B$15.44B$13.10B-$8.17B-$8.45B$5.10B$4.64B

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating cash flow $19.03B$18.81B$22.84B$24.94B$22.78B$17.59B$13.32B$13.43B$9.96B$7.04B
Depreciation and amortisation $762.0M$764.0M$752.0M$778.0M$803.0M$666.0M$464.0M$471.0M$425.0M$425.0M
Stock-based compensation $955.0M$911.0M$747.0M$671.0M$692.0M$753.0M$430.0M$421.0M$365.0M$353.0M
Capital expenditure $1.21B$974.0M$777.0M$695.0M$787.0M$798.0M$552.0M$638.0M$529.0M$479.0M
Investing cash flow -$6.64B-$20.82B-$2.01B-$623.0M-$2.34B-$37.56B$596.0M-$1.01B-$274.0M-$6.07B
Financing cash flow -$12.72B-$5.21B-$17.22B-$24.80B-$19.04B-$11.50B$18.71B-$14.40B-$5.51B-$3.93B
Dividends paid $11.66B$11.03B$10.54B$10.04B$9.26B$7.72B$6.37B$5.58B$4.11B$3.72B
Buybacks $980.0M$1.71B$1.97B$1.49B$934.0M$978.0M$629.0M$12.01B$1.41B$6.03B

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001551152-26-000008.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. 0 20B 40B 60B 80B Revenue, FY2016: 25.6B Gross profit, FY2016: 19.8B Net income, FY2016: 6B Revenue, FY2017: 28.2B Gross profit, FY2017: 21.2B Net income, FY2017: 5.3B Revenue, FY2018: 32.8B Gross profit, FY2018: 25B Net income, FY2018: 5.7B Revenue, FY2019: 33.3B Gross profit, FY2019: 25.8B Net income, FY2019: 7.9B Revenue, FY2020: 45.8B Gross profit, FY2020: 30.4B Net income, FY2020: 4.6B Revenue, FY2021: 56.2B Gross profit, FY2021: 38.8B Net income, FY2021: 11.5B Revenue, FY2022: 58.1B Gross profit, FY2022: 40.6B Net income, FY2022: 11.8B Revenue, FY2023: 54.3B Gross profit, FY2023: 33.9B Net income, FY2023: 4.9B Revenue, FY2024: 56.3B Gross profit, FY2024: 39.4B Net income, FY2024: 4.3B Revenue, FY2025: 61.2B Gross profit, FY2025: 43B Net income, FY2025: 4.2B FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue $25.64B $28.22B $32.75B $33.27B $45.80B $56.20B $58.05B $54.32B $56.33B $61.16B
Gross profit $19.81B $21.17B $25.04B $25.83B $30.42B $38.75B $40.64B $33.90B $39.43B $42.96B
Net income $5.95B $5.31B $5.69B $7.88B $4.62B $11.54B $11.84B $4.86B $4.28B $4.23B

Recent filings and events

  • Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
  • Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
  • Other event Item 8.01
  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Results announced Item 2.02
  • Regulation FD disclosure Item 7.01
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Results announced Item 2.02
  • Results announced Item 2.02
  • Other event Item 8.01
  • Other event Item 8.01
  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 2834

TickerCompanyMarket capP/ERevenue growth
LLY ELI LILLY & Co $1.20T 55.5x 44.7%
JNJ JOHNSON & JOHNSON $635.76B 23.9x 6.0%
MRK Merck & Co., Inc. $358.41B 20.0x 1.3%
ABT ABBOTT LABORATORIES $180.63B 27.9x 5.7%
PFE PFIZER INC $171.16B 22.1x -1.6%
VRTX VERTEX PHARMACEUTICALS INC / MA $132.80B 34.2x 8.9%
BMY BRISTOL MYERS SQUIBB CO $125.59B 17.8x -0.2%
REGN REGENERON PHARMACEUTICALS, INC. $82.76B 19.4x 1.0%